
Are FDA Reviewers Concerned About the Value of Clovis Oncology's EGFR Inhibitor Rociletinib?
A preliminary briefing document expresses concerns over clinical benefit over existing treatments, safety, and overall risk-benefit of the drug for the subset of lung cancer patients for whom the drug has been developed.
Ahead of the Oncologic Drugs Advisory Committee or ODAC meeting on April 12, 2016, the FDA has posted briefing materials on its website with respect to the accelerated approval of Clovis Oncology’s epidermal growth factor receptor (EGFR) inhibitor rociletinib, for treatment of patients with non-small cell lung cancer (NSCLC) who harbor a T790M mutation in EGFR, and whose disease has progressed after treatment.
The
A point of contention is the QTc prolongation and ventricular arryhtmias in patients exposed to the drug’s metabolites. The reviewers would like the advisory committee to discuss these issues during the meeting, along with the overall benefit-risk profile of rociletinib in the proposed patient population.
Clovis’ drug is not the first in its class—AstraZeneca’s osimertinib (Tagrisso) was
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.